Delivery Order SPE2DB22D2007-SPE2DB25FJ0GR

Award Date 3/31/25
Potential Completion Date 4/1/25
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for 1,000 units of the prescription drug Tamsulosin HCL 0.4 mg capsules. The contract has a ceiling value of $1,100.87 and a completion date of March 27, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the procurement of 1,000 units of the drug Tamsulosin Hydrochloride 0.4 mg capsules. The contract has a firm fixed price of $1,791.90 and a period of performance through March 26, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,566,352,432 units of Tamsulosin Hydrochloride 0.4 mg capsules. The contract has a ceiling value of $2,486.38 and a completion date of November 7, 2024. The award is not associated with a set-aside program. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
This is a firm-fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the provision of 1,000 capsules of the drug Tamsulosin Hydrochloride 0.4 mg. The contract has a ceiling value of $2,423.48 and an ultimate completion date of March 7, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. The delivery order has a firm fixed price of $2,520.38 and a period of performance through March 31, 2025. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a $4,194.81 firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 1,000 units of the drug Tamsulosin HCL 0.4 mg capsules. The contract has an ultimate completion date of March 31, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division,...
This is a $12,920.70 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of 1,000 units of the pharmaceutical product Tamsulosin HCl 0.4 mg capsules. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999, that enables the government to efficiently procure a comprehensive range of medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of the prescription drug Tamsulosin Hydrochloride 0.4 mg capsules. The fixed-price contract has a ceiling value of $1,489.87 and an ultimate completion date of April 1, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a $3,305.61 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of 4,567,341,633 units of Tamsulosin HCl 0.4 mg capsules to support military healthcare programs. The contract has an ultimate completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,456.09 firm fixed-price contract is for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules. The contract is not designated with any set-aside requirements, indicating open competition. It is associated with a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ0GR
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 1,000 units of Tamsulosin Hydrochloride 0.4 mg capsules. The contract has a ceiling value of $2,893.72 and runs through April 1, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 6/30/25, 11:06 AM